Regeneron Pharmaceuticals (REGN) Treasury Shares (2010 - 2026)

Regeneron Pharmaceuticals' Treasury Shares history runs 13 years deep, the most recent figure standing at $19.4 billion for Q1 2026.

• On a quarterly basis, Treasury Shares rose 19.7% year-over-year to $19.4 billion in Q1 2026; TTM through Mar 2026 was $19.4 billion, a 19.7% increase from a year earlier, with the FY2025 full-year figure at $18.6 billion, up 22.72% from the prior year.
• Treasury Shares advanced to $19.4 billion in Q1 2026 per REGN's latest filing, from $18.6 billion in the prior quarter.
• Across five years, Treasury Shares topped out at $34.7 million in Q1 2026 and bottomed at $19.9 million in Q1 2022.
• The 5-year median for Treasury Shares is $25.8 million (2024), against an average of $26.7 million.
• Across the five-year window, Treasury Shares soared 33.79% in 2022 and rose 14.36% in 2024, its largest moves.
• Year by year, Treasury Shares stood at $10.4 billion in 2022, then rose by 21.32% to $12.6 billion in 2023, then climbed by 20.76% to $15.2 billion in 2024, then advanced by 22.72% to $18.6 billion in 2025, then grew by 4.3% to $19.4 billion in 2026.
• Per Business Quant, the three latest REGN Treasury Shares figures stand at $19.4 billion (Q1 2026), $18.6 billion (Q4 2025), and $17.9 billion (Q3 2025).